Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors

Objective: Multiple myeloma patients who are relapsed or refractory to both proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have been reported to have poor outcomes. Bendamustine has been reported to have an antitumor effect in newly diagnosed as well as relapsed/refractory multiple m...

Full description

Bibliographic Details
Main Authors: Fevzi Fırat Yalnız, Nihan Akkoç, Ayşe Salihoğlu, M. Cem Ar, Şeniz Öngören, A. Emre Eşkazan, Teoman Soysal, Yıldız Aydın
Format: Article
Language:English
Published: Galenos Publishing House 2017-08-01
Series:Turkish Journal of Hematology
Subjects:
multiple myeloma
relapse refractory
bendamustine
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-56659

Internet

https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-56659

Similar Items